Weight loss and therapies targeting HC, TNF-α and CCL2, whether separately or in combination, may be beneficial to modulate rates of CSF secretion and/or resistance to CSF drainage pathways, both factors likely contributing to the raised ICP observed in female IIH patients with obesity. The gene discussed is TNF; the disease is obesity disorder.